- Home
- EDRY vs CLNN Comparison
EDRY vs CLNN Comparison
Compare EDRY & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- CLNN
- Stock Information
- Founded
- EDRY 2018
- CLNN 2012
- Country
- EDRY Greece
- CLNN United States
- Employees
- EDRY N/A
- CLNN N/A
- Industry
- EDRY Marine Transportation
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- CLNN Health Care
- Exchange
- EDRY Nasdaq
- CLNN Nasdaq
- Market Cap
- EDRY 27.3M
- CLNN 23.1M
- IPO Year
- EDRY N/A
- CLNN N/A
- Fundamental
- Price
- EDRY $10.26
- CLNN $4.24
- Analyst Decision
- EDRY
- CLNN Strong Buy
- Analyst Count
- EDRY 0
- CLNN 5
- Target Price
- EDRY N/A
- CLNN $33.00
- AVG Volume (30 Days)
- EDRY 1.3K
- CLNN 77.6K
- Earning Date
- EDRY 08-11-2025
- CLNN 08-14-2025
- Dividend Yield
- EDRY N/A
- CLNN N/A
- EPS Growth
- EDRY N/A
- CLNN N/A
- EPS
- EDRY N/A
- CLNN N/A
- Revenue
- EDRY $49,707,775.00
- CLNN $286,000.00
- Revenue This Year
- EDRY N/A
- CLNN N/A
- Revenue Next Year
- EDRY $28.27
- CLNN $1,753.57
- P/E Ratio
- EDRY N/A
- CLNN N/A
- Revenue Growth
- EDRY N/A
- CLNN N/A
- 52 Week Low
- EDRY $7.60
- CLNN $2.28
- 52 Week High
- EDRY $20.90
- CLNN $6.90
- Technical
- Relative Strength Index (RSI)
- EDRY 49.29
- CLNN 66.75
- Support Level
- EDRY $10.18
- CLNN $3.50
- Resistance Level
- EDRY $10.99
- CLNN $3.86
- Average True Range (ATR)
- EDRY 0.48
- CLNN 0.24
- MACD
- EDRY -0.07
- CLNN 0.04
- Stochastic Oscillator
- EDRY 17.45
- CLNN 78.33
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.